Tag Archives: President’s budget

A Weekly Advocacy Message from Mary Woolley: A thorn-laden rose

Dear Research Advocate,

The President’s budget is out and it’s a mixed bag. First, the good news. NSF was given a significant funding boost, $593M over 2012 levels, NIH funding was increased by $470M, and AHRQ, via budget trade-offs, looks to have been boosted by $64M. The increases are from FY12 to FY14, since the President’s budget replaces sequestration in a different way than either Congressional body (see more below). The not so good news in the President’s budget is that other health research agencies did not fare well. The CDC budget was cut deeply, especially prevention programs. FDA was essentially flat -funded. And entitlement-reform may pose a challenge to innovation.

The different ways the three budgets, President, Senate and House, deal with sequestration is symptomatic of the continuing failure to reach agreement on anything resembling comprehensive legislation, including so-called “grand bargains.” The fact that there is so much attention to medical research in the President’s budget, as well as on the floor of the Senate recently, and from a number of Members of Congress, speaks to the progress the research advocacy community is making in bringing medical research to the forefront. But success to date has not diminished the need for heightened advocacy for public health and social sciences research, nor the imperative of carefully evaluating the full consequences of changes to entitlements. The three budgets deal with entitlements in different ways, but with similar ill-effect when it comes to innovation. There is no question that we need tax and entitlement reform, and no question that sequestration must be eliminated; however, we cannot thrive as a nation or succeed at deficit reduction if entitlement reforms come at the expense of private sector innovation.  See our statement on the President’s budget here.

Speaking of social science research — so clearly under fire —  it is not too late to RSVP to a Capitol Hill briefing we are co-hosting tomorrow on economic research. There is a terrific lineup of speakers.

I know many of you attended the Rally for Medical Research on Monday here in Washington,  a coalition effort led by the AACR. Thousands of like-minded research advocates and a wonderful array of speakers, including our board chair, The Honorable John Porter, gathered to crank up the volume for research. In his remarks, Mr. Porter urged advocates to get fighting mad or we risk continued cuts from Congress. Review his remarks here; then, take a moment to participate in the Rally’s on-going text messaging campaign to urge Congress to assign a high priority to medical research. You can view press coverage of the event and the full list of speakers. During the event, social media attention was strong — messaging trended #2 globally on Twitter.  That’s the level of volume and attention we must continue to maintain if we want to see a happy ending to budget negotiations.  Please do your part!

More than 50 Nobel laureates are doing their part; they have joined forces to send a letter to Congress urging them to fund, rather than freeze or cut, research and development. In the letter, the Laureates cite their deep concern over reduced funding levels and the negative impact this will have on the next generation of scientists and ultimately, upon our nation’s economic vitality. It’s a good reminder that the full science community is in this battle together.  Take a moment now to echo their message by urging your representative to sign on the Markey-McKinley letter calling for a $1.5B boost to NIH funding. Click here to see the list of current signers. If your representative is on the list, be sure to thank them for standing up for research. If they haven’t signed-on yet, click here to send them a message.

On Monday, we released our latest national poll, focused on chronic pain and drug addiction. Surprisingly, only 18% of the poll respondents believe chronic pain is a major health problem, yet two-thirds know someone who has sought relief from chronic pain. Huge majorities are concerned about  abuse or misuse of prescription medications; the need for better understanding of how to address chronic pain literally cries out for research. You can view our media release here.

Sincerely,

Mary Woolley

Advertisements

Statement from Research!America President and CEO Mary Woolley on President Obama’s FY14 Budget Proposal

The president’s FY14 budget proposal offers a lifeline for medical research to replace sequestration’s damaging footprints. The budget includes $31.3 billion for the National Institutes of Health, as well as increases for the Food and Drug Administration and National Science Foundation. These increases would take our nation in the right direction, but we’re concerned that budget proposals from Congress – one from each of the House and Senate – unlike the president, fail to reverse sequestration. Sequestration, 10 years of across-the-board spending cuts, will drag our nation down from its leadership position in research and development as other countries aggressively ramp up investments, attracting American businesses and young scientists concerned that federal funding is on the decline, that the U.S. no longer prioritizes research. Policy makers must start acting in the best interests of this nation and tackle tax and entitlement reform to end sequestration.

Our nation has the most sophisticated medical research ecosystem in the world; yet our elected officials have ignored the short- and long-term consequences of dismantling it via sequestration – more deaths from preventable diseases, increased joblessness and soaring health care costs as more Baby boomers become afflicted with Alzheimer’s, cancer, heart disease and other life-threatening, costly illnesses.

While the president’s budget increases federally-funded medical research, Congress and the administration must look more deeply into the consequences of dramatic cuts to Medicare Parts B and D, which cover crucial medical innovations including prescription drugs, biologics, and medical devices.  If Medicare undervalues these preventative, diagnostic, and treatment tools, access and innovation will both suffer. The counterproductive effect of slowed innovation and access barriers could be increased hospital and other health care costs. We’re also disappointed that the president’s budget cuts funding for the Centers of Disease Control and Prevention which is already operating on a severely depleted budget.  Cuts to the Agency for Healthcare Research and Quality which identifies waste and duplication in our health care system while combating deadly medical errors are also a strategic mistake.  Policymakers must tread carefully in the coming weeks to avoid decision-making that will endanger the health and economic prosperity of our country.

# # #